King-Jones Heidy sold 2,100 shares of Spyre Therapeutics, Inc. at $92.70 for −$195k on Oct 1, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
See Remarks
See Remarks
Filed Oct 2, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$194,670Shares × reported price
Shares traded
2,100Common Stock
Price per share
$92.70Reported price. Read footnotes for ranges.
% of reported position traded
27.83%This security and ownership context
Holdings after
5,445Direct
Trade date
Oct 1, 2026Sell
Filed
Oct 2, 2026, 9:30 PM ET2-day reporting delay
Accession
0001636282-26-000119Code S · Transaction 236180
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 7,545 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Oct 1, 2026Option exercise28,933$14.50$419,528.50Trade 236176
Oct 1, 2026Sell400$89.24−$35,696Trade 236177
Oct 1, 2026Sell16,605$90.35−$1,500,261.75Trade 236178
Oct 1, 2026Sell7,228$91.35−$660,277.80Trade 236179
Oct 1, 2026Sell2,600$93.46−$242,996Trade 236181
Oct 1, 2026Option exercise28,933$0.00$0Trade 236182
7 transaction rows in this filing. Joint filers share the same rows.

SYRE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SYRE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −5%1w ago −6.5%1d ago −4.5%
Returns since7d −8%30d +3.6%90d180d1y

Footnotes in full

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F7: This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.